1-20 of 174
Wojciech Jurczak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients

Free
Wojciech Jurczak, Michal Kwiatek, Jaroslaw Czyz, Ederson de Mattos, Ki-Seong Eom, Alexander Egle, Anna Panovská, Zhanet Grudeva-Popova, Hsuan-Jen Shih, Luis Felipe Casado Montero, Paolo Sportoletti, Vu Minh Hua, James D'Olimpio, Shinsuke Iida, Rodrigo Ito, Katherine Bao, Anne Fink, Weiji Su, Amy Ruppert Stark, Alejandro Levy, Tomasz Wrobel
Journal: Blood
Blood (2025) 146 (Supplement 2): LBA-3.
https://doi.org/10.1182/blood-2025-LBA-3
Published: 2025
Journal Articles

Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor

Free
Jennifer Woyach, Lugui Qiu, Sebastian Grosicki, Tomasz Wrobel, Marcelo Capra, Jaroslaw Czyz, Shuhua Yi, Ki-Seong Eom, Anna Panovská, Wojciech Jurczak, Kamel Laribi, Lutz Jacobasch, Ross Baker, Richy Agajanian, Alejandro Berkovits, Muhit Özcan, Stephane Lepretre, Catherine Coombs, Paula Cramer, Katharine Lewis, Marisa Hill, Katherine Bao, Yuanyuan Bian, Amy Ruppert Stark, Ching Ching Leow, William Wierda
Journal: Blood
Blood (2025) 146 (Supplement 1): 683.
https://doi.org/10.1182/blood-2025-683
Published: 2025
Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Free
Michael Wang, Jonathon Cohen, Nirav Shah, Wojciech Jurczak, Pier Luigi Zinzani, Chan Cheah, Chaitra Ujjani, Youngil Koh, Won Seog Kim, Sunita Dwivedy Nasta, Ian Flinn, Benoit Tessoulin, Shuo Ma, Alvaro Alencar, David Lewis, Jennifer Woyach, Kami Maddocks, Krish Patel, Yucai Wang, Joanna Rhodes, Constantine Tam, John Seymour, Hirokazu Nagai, Julie Vose, Bita Fakhri, Marc Hoffmann, Francisco Hernandez-Ilizaliturri, Andrew Zelenetz, Anita Kumar, Talha Munir, Donald Tsai, Paolo Abada, Minna Balbas, Jian Li, Ying (denise) Wang, Lindsey Roeker, Toby Eyre
Journal: Blood
Blood (2025) 146 (Supplement 1): 665.
https://doi.org/10.1182/blood-2025-665
Published: 2025
Journal Articles

Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 study

Free
Michael Wang, Yuqin Song, Olivier Hermine, Yuerong Shuang, Wojciech Jurczak, João Samuel de Holanda Farias, Carolina Mahuad, Muhit Ozcan, Ron D. Jachimowicz, Tianlei Chen, Elena Ivanova, Xiaotong Li, Gabriel Man, Priscille Bourquelot, Remus Vezan, Toby Eyre
Journal: Blood
Blood (2025) 146 (Supplement 1): 663.
https://doi.org/10.1182/blood-2025-663
Published: 2025
Journal Articles

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Free
Eliza Hawkes, Joanna Romejko-Jarosinska, Wojciech Jurczak, Sunil Iyengar, Abel Costa, Nimish Shah, Monique Menzies Wojtowicz, Allison Winter, Adam Witkowski, Neil Chua, Ana Jiménez Ubieto, John Kuruvilla, Diego Villa, Chan Cheah, Andre Goy, Elise Chong, Andrew Wood, Rachel Fletcher, Stefanie Meyer, Rebecca Silva, Simon Rule, Michael Wang
Journal: Blood
Blood (2025) 146 (Supplement 1): 884.
https://doi.org/10.1182/blood-2025-884
Published: 2025
Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Free
Chan Cheah, Manish Patel, Toby Eyre, Wojciech Jurczak, David Lewis, Thomas Gastinne, Shuo Ma, Jonathon Cohen, Krish Patel, Jennifer Brown, Lydia Scarfo, Talha Munir, Ewa Lech-Maranda, Marc Hoffmann, Chaitra Ujjani, Bita Fakhri, Michael Wang, Koji Izutsu, Hirokazu Nagai, Constantine Tam, Joanna Rhodes, Julie Vose, Matthew McKinney, James Gerson, Minal Barve, Bryone Kuss, Youngil Koh, Aisling Barrett, Steven Treon, Jorge Castillo, John Seymour, Amy Ruppert Stark, Samuel McNeely, Richard Walgren, Donald Tsai, Katherine Bao, Binoj Chandrasekharan Nair, Jennifer Woyach, Lia Palomba
Journal: Blood
Blood (2025) 146 (Supplement 1): 226.
https://doi.org/10.1182/blood-2025-226
Published: 2025
Journal Articles

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

Free
Constantine Tam, Talha Munir, Tadeusz Robak, Jennifer Brown, Brad Kahl, Paolo Ghia, Stephen Opat, Patricia Walker, Masa Lasica, Ian Flinn, Jiayi Shen, Nataliya Kuptsova-Clarkson, Marcus Lefebure, Jamie Hirata, Wojciech Jurczak, Mazyar Shadman
Journal: Blood
Blood (2025) 146 (Supplement 1): 2129.
https://doi.org/10.1182/blood-2025-2129
Published: 2025
Journal Articles

Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL): Up to 6 years of follow-up with the long-term extension (LTE1)

Free
Constantine Tam, Andrzej Mital, Robert Weinkove, Wojciech Jurczak, Xin Yan, Nataliya Kuptsova-Clarkson, Tian Tian, Megan Wang, Jamie Hirata
Journal: Blood
Blood (2025) 146 (Supplement 1): 2123.
https://doi.org/10.1182/blood-2025-2123
Published: 2025
Journal Articles

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Free
William Wierda, Jennifer Brown, Paolo Ghia, Lindsey Roeker, Krish Patel, Toby Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine Tam, John Seymour, Benoit Tessoulin, Nirav Shah, Chaitra Ujjani, Bita Fakhri, Catherine Coombs, Ian Flinn, Manish Patel, Sunita Dwivedy Nasta, Jonathon Cohen, Alvaro Alencar, Chan Cheah, Shuo Ma, Joanna Rhodes, Deepa Jagadeesh, Pier Luigi Zinzani, Anders Österborg, Koji Izutsu, Noriko Fukuhara, Donald Tsai, Paolo Abada, Minna Balbas, Jian Li, Ying (denise) Wang, Wojciech Jurczak, Jennifer Woyach
Journal: Blood
Blood (2025) 146 (Supplement 1): 2115.
https://doi.org/10.1182/blood-2025-2115
Published: 2025
Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results

Free
Grzegorz Nowakowski, Marc Hoffmann, Javier Munoz, Jason Westin, Alejandro Martin Garcia-Sancho, Michal Kwiatek, Wojciech Jurczak, Maria Bouzani, Muhamad Alhaj Moustafa, Akshay Sudhindra, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Serena Perna, Theodoros Vassilakopoulos
Journal: Blood
Blood (2025) 146 (Supplement 1): 476.
https://doi.org/10.1182/blood-2025-476
Published: 2025
Journal Articles

Integrating patient and clinician perspectives to advance R/R CLL care: Results of a multi-pronged global initiative

Free
Carmine Deluca, Michael Beyer, Marina Wanes, Jessica Massey, Meghan Thompson, Talha Munir, Wojciech Jurczak, Brian Koffman
Journal: Blood
Blood (2025) 146 (Supplement 1): 6428.
https://doi.org/10.1182/blood-2025-6428
Published: 2025
Journal Articles

Genomic assessment of acquired mutations in participants with CLL/SLL treated with nemtabrutinib in the Phase 2 bellwave-003 study

Free
Thomas Kipps, Guilherme Perini, David Lavie, Ricardo Bigni, Almudena Navarro-Bailón, Ohad Benjamini, Riva Fineman, Christof Schneider, Sarit Assouline, Carolyn Owen, Andras Masszi, Juan Dupont, Mackenzie Edmondson, Cai Chen, Razvan Cristescu, Nicole Myer, Yan Xu, Jing Yang, Mohammed Z.H. Farooqui, Wojciech Jurczak
Journal: Blood
Blood (2025) 146 (Supplement 1): 797.
https://doi.org/10.1182/blood-2025-797
Published: 2025
Journal Articles

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

Free
Zulfa Omer, Alexey Danilov, Francesco Forconi, Talha Munir, Mary Gleeson, Nirav Shah, Graham Collins, Alvaro Alencar, Jane Robertson, Jonathon Cohen, Karan Dixit, Danielle Brander, John Byrd, Allison Winter, Jeffery Smith, Dima El-Sharkawi, Michal Kwiatek, Iwona Hus, Prioty Islam, Sebastian Grosicki, Michael Tees, Thorsten Zenz, Joanna Romejko-Jarosinska, Sarah Injac, Wojciech Jurczak
Journal: Blood
Blood (2025) 146 (Supplement 1): 86.
https://doi.org/10.1182/blood-2025-86
Published: 2025
Journal Articles

Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma

Free
Yasmin Karimi, Chan Cheah, Julie Vose, Michael Roost Clausen, David Cunningham, Umar Farooq, Tatyana Feldman, Herve Ghesquieres, Wojciech Jurczak, Kim Linton, Tycel Phillips, Won Seog Kim, Pegah Jafarinasabian, Barbara D'Angelo Månsson, Milan Geybels, Christian Eskelund, Martin Hutchings, Catherine Thieblemont
Journal: Blood
Blood (2025) 146 (Supplement 1): 5513.
https://doi.org/10.1182/blood-2025-5513
Published: 2025
Journal Articles

Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response

Free
Chan Cheah, Tycel Phillips, Wojciech Jurczak, Tae Min Kim, Kim Linton, Julie Vose, Jieying Jiang, Mohammad Atiya, Christian Eskelund, Charles Kearns, Catherine Thieblemont
Journal: Blood
Blood (2025) 146 (Supplement 1): 5511.
https://doi.org/10.1182/blood-2025-5511
Published: 2025
Journal Articles

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Free
Umberto Vitolo, Johannes Duell, Juan Miguel Bergua Burgues, Wojciech Jurczak, Michal Kwiatek, Marie Maerevoet, Sergio Ortegon Alcaide, David Belada, Won Seog Kim, Richard Greil, Raul Cordoba, Juan-Manuel Sancho, David Sibon, Catherine Thieblemont, Takahiro Kumode, Monica Wielgos-Bonvallet, Tony Jiang, Yanli Wang, Stephanie McGoldrick, Evelyn Guo, Franck Morschhauser, Sherida Woei-A-Jin
Journal: Blood
Blood (2025) 146 (Supplement 1): 63.
https://doi.org/10.1182/blood-2025-63
Published: 2025
Journal Articles

Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003

Free
Philippe Armand, Seung Tae Lee, Wojciech Jurczak, Don Stevens, Sylvain Choquet, Herve Ghesquieres, Lalita Norasetthada, Antonio Pinto, Güray Saydam, Heng Zhou, Nishitha Reddy, Rushdia Yusuf, Muhit Ozcan
Journal: Blood
Blood (2025) 146 (Supplement 1): 3745.
https://doi.org/10.1182/blood-2025-3745
Published: 2025
Journal Articles

An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Free
Herve Ghesquieres, Malgorzata Krawczyk-Kulis, Dominik Chraniuk, Michal Kwiatek, Hendrik Nogai, Chadi Saba, Adam Falkowski, Katarzyna Kucharz, Michal Kulesza, Ruth Curley, Gary Wilkinson, Przemyslaw Juszczynski, Francesco Bertoni, Daniela Bellarosa, Antonio Galleu, Ira Gupta, Monika Dlugosz-Danecka, Wojciech Jurczak, Guillaume Cartron, Grzegorz Nowakowski
Journal: Blood
Blood (2025) 146 (Supplement 1): 5481.
https://doi.org/10.1182/blood-2025-5481
Published: 2025
Journal Articles

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma

Free
Theodoros Vassilakopoulos, Javier Munoz, Huiqiang Huang, Ichiro Kawashima, Sung Yong Oh, Wojciech Jurczak, Juan Miguel Bergua Burgues, Ou Bai, Alejandro Berkovits, Keshu Zhou, Marc Hoffmann, Jason Westin, Maria Bouzani, Michal Kwiatek, Tai-Chung Huang, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Adrien Petel, Serena Perna, Grzegorz Nowakowski
Journal: Blood
Blood (2025) 146 (Supplement 1): 3704.
https://doi.org/10.1182/blood-2025-3704
Published: 2025
Journal Articles

Nemtabrutinib in participants with relapsed or refractory follicular lymphoma: Updated efficacy and safety from cohort g of the phase 2 bellwave-003 study

Free
Wojciech Jurczak, Ana Basquiera, Isabelle Fleury, Sujun Gao, Arpad Illes, Andras Masszi, Antonio Pinto, Sanne Lugthart, Omur Sevindik, Iryna Kriachok, Elizabeth Phillips, Fei Li, Chan Cheah, Yan Xu, Mohammed Z.H. Farooqui, Jing Yang, Fangfang Lv
Journal: Blood
Blood (2025) 146 (Supplement 1): 3570.
https://doi.org/10.1182/blood-2025-3570
Published: 2025